raxibacumab

Known as: raxibacumab monoclonal antibody, human 
 

Topic mentions per year

Topic mentions per year

2009-2017
024620092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Anthrax, caused by Bacillus anthracis (B anthracis), poses a potential threat as a bioterror agent because after inhalation, the… (More)
Is this relevant?
2015
2015
Although antibiotics treat bacteremia in inhalational anthrax, pathogenesis is mainly driven by bacterial exotoxins. Raxibacumab… (More)
Is this relevant?
2015
2015
On December 14, 2012, the FDA approved Raxibacumab, the first monoclonal antibody product developed under Project BioShield to… (More)
Is this relevant?
2015
2015
BACKGROUND Lethal and edema toxin contribute to shock and lethality with Bacillus anthracis. We showed previously in a 96-h… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
Anthrax is a highly contagious and potentially fatal human disease caused by Bacillus anthracis, an aerobic, Gram-positive, spore… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2013
2013
Inhaled Bacillus anthracis spores germinate and the subsequent vegetative growth results in bacteremia and toxin production… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2010
2010
IMPORTANCE OF THE FIELD Inhalational anthrax is a disease with a high lethality potential and current therapeutic interventions… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Inhalational anthrax caused by Bacillus anthracis is associated with high mortality primarily due to toxin-mediated… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Review
2009
Review
2009
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. HGS is currently… (More)
Is this relevant?